About InnoDrug
InnoDrug is a fully integrated biopharmaceutical company with a focus on drug discovery, clinical development, and commercial operations. Led by internationally renowned scientist Professor Zhu Yizhun, and driven by cutting-edge scientific exploration, we are committed to developing globally competitive First-in-Class innovative therapies.
more
Nearly 50 global patents
Building a robust IP moat
Core products under dual U.S.–China filings
Global vision and execution
A PhD team of over 100 members
From leading academic institutions
Backed by a National Key Laboratory
Building an integrated R&D engine
Key Achievements
Leonurine Sulfate (SCM-198)
World’s first CD36-targeted anti-cardiovascular inflammation
first-in-class drug
Currently in Phase II clinical trials
Propargylcysteine (ZYZ-802)
Target selected as one of Science’s Top 10 Global Drug Targets
Currently in Phase I clinical trials
Latest News
more →
Latest News
2025 Academic Committee Meeting of the Laboratory of Natural Drug Discovery and Industrialization Successfully Held
The 2025 Academic Committee Meeting of the Laboratory for Natural Drug Discovery and Industrialization was successfully held recently in Meeting Room N502 at Macao University of Science and Technology (MUST). The meeting was chaired by Academician Yang Baofeng of the Chinese Academy of Engineering and renowned pharmacologist, and led by Academician Zhu Yizhun, Member of the European Academy of Sciences and Arts, Associate Vice President of MUST and Dean of the Faculty of Pharmacy, Chief Scientist of China’s National Basic Research Program (973 Program), and Director of the Laboratory for Natural Drug Discovery and Industrialization. A number of leading experts
Top-Tier Journal Research: Garlic Outperforms Metformin in Longevity Extension
html On December 19, 2025, the University of Seville in Spain published a research paper in the journal Cell Metabolism. This study is the first to demonstrate in mammals that diallyl sulfide (H2S) from garlic can continuously generate hydrogen sulfide through non-enzymatic pathways, extending mouse lifespan by 11.4%—a greater extension than metformin (5.8%)—while improving metabolic, motor, and cognitive functions. The research team also analyzed human data, finding that among patients with multiple comorbidities, higher plasma protein persulfidation levels were associated with stronger grip strength and lower triglyceride levels, further supporting the potential role of H2S in maintaining human health. The
In Less Than a Month, Marketing Applications for Over 100 Generic Drugs Rejected
Recently, the National Medical Products Administration (NMPA) has been frequently publishing delivery notices for drug notification letters on its official website. Generally speaking, delivery of such a notification letter indicates that a marketing authorization application has been “not approved,” or that the applicant has proactively withdrawn the application after anticipating it would not pass review. Based on statistics compiled by Yicai (First Financial) from the NMPA website, from the beginning of December through December 19, the list involved 167 drugs, of which 102 were chemical generic drug applications (based on acceptance numbers starting with CYHS). In other words, in December,
Tender Information
Tender Home
Invitation to Tender: SPRC Project
1. Tender Project This tender is for the "InnoDrug Group Limited SPRC Preclinical Animal Study Project," focused on non-clinical animal studies for SPRC. 2. Project Overview and Scope of Tender This project consists of preclinical animal studies for SPRC conducted by InnoDrug Group Limited. The project has completed PCC confirmation. To meet the requirements for a New Drug Investigational New Drug (IND) application in China, the project plans to engage a preclinical Contract Research Organization (CRO) to complete drug safety evaluation research services. To satisfy the requirements for independent drug registration and marketing approval, this project plans to assess the safety of SPRC through rodent and non-rodent models to determine the safety of clinically relevant parameters. The contracted party shall be responsible for the entire animal study process, including experimental protocol design, organization, implementation, execution, inspection, documentation, archiving, and reporting, ensuring that studies comply with Good Laboratory Practice for Non-Clinical